Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To assess the efficacy, hypoglycaemia risk and other safety markers of linagliptin as an additional therapy in older patients (aged ≥70 years) inadequately controlled with basal insulin.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Diabetes Obes Metab

Title: Diabetes, obesity & metabolism

Publisher: Wiley-Blackwell

ISSN (Electronic): 1463-1326

ISSN (Print): 1462-8902

Publication date (Electronic): Sep 2015

Volume: 17

Issue: 9

Affiliations

[1 ] Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA.

[2 ] Division of Diabetology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany.

[3 ] Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

[4 ] Center for Metabolic Research, Veterans Affairs San Diego Healthcare System, University of California San Diego School of Medicine, San Diego, CA, USA.